Previous close | 3.4700 |
Open | 3.5900 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 3.5300 - 3.6500 |
52-week range | 3.2600 - 13.8400 |
Volume | |
Avg. volume | 307,537 |
Market cap | 7.556B |
Beta (5Y monthly) | 0.66 |
PE ratio (TTM) | 17.00 |
EPS (TTM) | 0.2100 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2023 ("Reporting Period").
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'.
(Bloomberg) -- Traders have piled into options on WuXi Biologics Cayman Inc. to protect against potential swings, with its sister company’s earnings in focus on Tuesday.Most Read from BloombergApple Is in Talks to Let Google Gemini Power iPhone AI FeaturesTrump Rules Out Vivek Ramaswamy as Running Mate as He Eyes New TeamNvidia Unveils Successor to Its All-Conquering AI ProcessorMusk Says His Ketamine Prescription Is in Investors’ Best InterestsEvergrande’s Alleged $78 Billion Fraud Is Among Big